-
Exondys Sales, Takeover Speculation Fuel Sarepta Therapeutics
Friday, April 28, 2017 - 11:31am | 380Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are up more than 6.5 percent Friday after the company reported first-quarter net revenue from EXONDYS 51 of $16.3 million and guided for $95 million in revenue for the full year, up from previous guidance of $80 million. In addition to the revenue beat...
-
Analysts Prescribe A Downgrade For Pfizer Stock
Wednesday, November 2, 2016 - 12:24pm | 370Read More...Argus has downgraded Pfizer Inc. (NYSE: PFE) to Hold from Buy on a weaker outlook, pipeline setbacks and increased competition. Further, the discontinuation of separation plans was also a key reason behind the downgrade, as the brokerage believes the split would have improved business performance...
-
5-Month Timeline: A Look Back At Medivation's Takeover Story
Monday, August 22, 2016 - 8:46am | 524Read More...Pfizer Inc. (NYSE: PFE) confirmed Monday it has entered into an agreement to acquire Medivation Inc (NASDAQ: MDVN) for $81.50 a share. The announcement puts an end to months of speculation. Sanofi SA (ADR) (NYSE: SNY) announced in late April it sent Medivation's Board of Directors an offer...
-
Short-Sellers Shy Away From These 2 Biotechs This Settlement Period
Thursday, July 28, 2016 - 10:03am | 481Read More...Short investor interest in a number of biotech stocks dwindled the first two weeks of July, with two stocks leading the trend with share prices for each growing modestly. Biotechnology is one of those segments that has had a rough go so far this year. And yet, short-selling interest in many of...
-
Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences
Sunday, July 24, 2016 - 4:03pm | 873Read More...Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...
-
Biogen And Gilead Sciences Buck Biotech Short Interest Trend
Sunday, June 12, 2016 - 2:35pm | 588Read More...Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of both of these stocks rose sharply during the two-week period. Short sellers shied away from many of the...
-
Sanofi Names Candidates, Committed To Replacing Medivation's Entire Board
Wednesday, May 25, 2016 - 9:04am | 305Read More...Reuters reported early Wednesday morning that Sanofi SA (ADR) (NYSE: SNY) is preparing a list of candidates it plans to put forward to replace Medivation Inc (NASDAQ: MDVN)'s entire board of directors. Sanofi has threatened to do so after Medivation rejected its $9.3 billion bid to acquire the...
-
Short Interest Surges In Illumina And Vertex Pharmaceuticals
Friday, May 13, 2016 - 1:26pm | 550Read More...Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of one of those two stocks slumped more than 22 percent during the period. Short sellers shied away from many of...
-
Short Sellers Dump Amgen And Baxalta
Friday, May 13, 2016 - 8:56am | 539Read More...Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out as leaders of that trend in those two weeks. Shares of one of those two stocks rose while the other slumped during the period. Short sellers moved on only a few of the leading...
-
Here's What Medivation Said In Its Rejection Letter To Sanofi
Friday, April 29, 2016 - 2:38pm | 361Read More...Medivation Inc (NASDAQ: MDVN) disclosed on Friday a letter it has written to Sanofi SA (ADR) (NYSE: SNY) with regards to its acquisition offer to buy the company for $52.50 per share. Medivation started off by stating its Board of Directors unanimously rejected Sanofi's proposal to fully...
-
Sanofi Wants To Acquire Medivation For $52.50 Per Share
Thursday, April 28, 2016 - 10:11am | 271Read More...Sanofi SA (ADR) (NYSE: SNY) announced on Thursday that it has sent a letter to Medivation Inc (NASDAQ: MDVN) in which it confirmed an offer to acquire the company for $52.50 per share was proposed on April 15 and initial discussions regarding a merger were held in late March. Shares of Medivation...
-
Short Sellers Dump Vertex, Load Up On Baxalta
Thursday, April 28, 2016 - 8:34am | 588Read More...Short interest in many leading biotech stocks declined in the most recent period. Bucking that trend is a biotech company that soon will be acquired by an overseas peer. Short sellers retreated most sharply from a biotech that some analysts now see as a value stock. Between the March 31 and April...
-
Medivation Ticks Up 3%, AstraZeneca Said To Be Also Interested In Acquisition
Monday, April 18, 2016 - 8:31am | 203Read More...Shares of Medivation Inc (NASDAQ: MDVN) were trading higher by more than 3 percent early Monday following reports the company is being eyed as an acquisition target by more than one potential buyer. Medivation has already received interest from Sanofi SA (ADR) (NYSE: SNY) and analysts suggested...
-
Medivation Drops 12% After Congress Asks To Examine Xtandi Drug Price
Tuesday, March 29, 2016 - 10:18am | 189Read More...Shares of Medivation Inc (NASDAQ: MDVN) were trading lower by more than 6 percent heading into Tuesday's market open as the company's drug pricing have come under scrutiny by the U.S. Congress. According to ABC News, a group of U.S. lawmakers initiated a campaign to potentially lower the price of...
-
More Wild Short Interest Swings In Biotech Stocks
Sunday, December 13, 2015 - 5:52pm | 924Read More...Short interest moves in leading biotech stocks were mixed in the most recent period. However, Illumina, Inc. (NASDAQ: ILMN) and Baxalta Inc (NYSE: BXLT) saw sharp increases in their short interest in late November. Short sellers appeared to lose interest in Juno Lighting LLC (NASDAQ: JUNO) late in...
